A Comparison of CD4 T Cell Induction and Antibody Responses Between a Pure Hemagglutinin Influenza Vaccine (rHA, Protein Sciences Corp) and Licensed Subvirion Influenza Vaccine Made in Eggs (Sanofi) or Cell Culture (Novartis) in Healthy Adults.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza vaccine (Optaflu) (Primary) ; Influenza virus RIV3 vaccine-(FluBlok) (Primary) ; Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary)
Indications Influenza virus infections
Focus Pharmacodynamics

Most Recent Events

07 Dec 2020 Status changed from recruiting to active, no longer recruiting.
09 Oct 2019 Results (n=85) published in the Clinical Infectious Diseases.
12 Apr 2019 Planned End Date changed from 30 Jun 2020 to 30 Jun 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight